RNAZ (STOCKS)
TransCode Therapeutics, Inc. Common Stock
$3.497900
+0.127900 (+3.80%)
Prev close: $3.370000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Philippe P. Calais
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3.68M
- Employees
- 7
- P/E (TTM)
- -0.07
- P/B (TTM)
- 2.47
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2024 (Q4)
|
$-150.64 | $-91.68 | -58.9624 | -64.31% |
|
Sep 2024 (Q3)
|
$-147.84 | $-461.82 | +313.9752 | +67.99% |
|
Jun 2024 (Q2)
|
$-665.28 | $-546.64 | -118.6416 | -21.70% |
|
Mar 2024 (Q1)
|
$-498.96 | $-659.74 | +160.7760 | +24.37% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $2.66M |
| Operating Expenses | $42.56M |
| Research and Development | $16.31M |
| Other Operating Expenses | $26.25M |
| Operating Income/Loss | -$42.56M |
| Income/Loss From Continuing Operations After Tax | -$40.36M |
| Income/Loss From Continuing Operations Before Tax | -$39.90M |
| Income Tax Expense/Benefit | $457.38K |
| Net Income/Loss | -$40.36M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$40.36M |
| Net Income/Loss Available To Common Stockholders, Basic | -$43.70M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $3.34M |
| Preferred Stock Dividends And Other Adjustments | $3.34M |
| Basic Earnings Per Share | -$50.33 |
| Diluted Earnings Per Share | -$50.33 |
| Basic Average Shares | 2,658,754 |
| Diluted Average Shares | 2,658,754 |
| Assets | $157.16M |
| Current Assets | $16.75M |
| Noncurrent Assets | $140.42M |
| Fixed Assets | $346.75K |
| Intangible Assets | $114.30M |
| Other Non-current Assets | $25.77M |
| Liabilities | $12.64M |
| Current Liabilities | $5.38M |
| Noncurrent Liabilities | $7.27M |
| Equity | $1.25M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.25M |
| Liabilities And Equity | $157.16M |
| Net Cash Flow From Operating Activities | -$21.40M |
| Net Cash Flow From Operating Activities, Continuing | -$21.40M |
| Net Cash Flow | $7.02M |
| Net Cash Flow, Continuing | $7.02M |
| Comprehensive Income/Loss | -$40.36M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$40.36M |
| Other Comprehensive Income/Loss | $0.00 |